miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies

BACKGROUND: BCL-xL is an anti-apoptotic BCL-2 family protein that inhibits apoptosis and is overexpressed in many cancers. We have reported that acquired resistance to the BCL-2 inhibitor ABT-199 (venetoclax) is associated with increased BCL-xL expression. Yet, how BCL-xL mediates chemoresistance in...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-harbi, Sayer, Choudhary, Gaurav S., Ebron, Jey Sabith, Hill, Brian T., Vivekanathan, Nagarajavel, Ting, Angela H., Radivoyevitch, Tomas, Smith, Mitchell R., Shukla, Girish C., Almasan, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632834/
https://www.ncbi.nlm.nih.gov/pubmed/26537004
http://dx.doi.org/10.1186/s12943-015-0460-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632834/
https://www.ncbi.nlm.nih.gov/pubmed/26537004
http://dx.doi.org/10.1186/s12943-015-0460-8

Ejemplares similares